Pharnext to Present PXT864 Data at the Alzheimer's Association International Conference 2017
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT864, the Company’s lead PLEODRUG™, in development for the treatment of Alzheimer’s disease (AD), will be presented in two posters at the Alzheimer's Association International Conference 2017 (AAIC), July 16-20, in London, England.
Details are as follow:
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice-daily. PXT864 acts through a new mechanism of action that targets metabolic imbalance in the brain of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned.
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
+33 (0)1 44 54 36 64
René Goedkoop, +33 (0)1 41 09 22 30
Chief Medical Officer
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (U.S.)
Financial Communication (France)
Emmanuel Huyn, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
GLOBAL-BLOCKCHAIN-ASSOC10.12.2018 16:02 | Pressemeddelelse
The Largest Blockchain Conference in Asia to Be Held 30–31 January in Yokohama, Japan
GA-GLOBAL-PAYMENTS10.12.2018 14:32 | Pressemeddelelse
Global Payments’ TouchNet Business Named “Partner of the Year” by Ellucian
FL-CTS-ENGINES10.12.2018 14:02 | Pressemeddelelse
CTS Engines Hires Tom Bode as Senior Vice President, Operations
TRACXPOINT10.12.2018 12:02 | Pressemeddelelse
Tracxpoint Signed a Major Agreement to Deploy its Artificial Intelligence Cart (AiC®) Platform at CONAD, One of the Largest and Most Sophisticated Supermarket Chains in Italy with 3,000 Locations in Lieu of Amazon Go after Intensive Study
JETEX10.12.2018 10:54 | Pressemeddelelse
Jetex Now the Exclusive Dealer in the Middle East for Hi-Tech New HondaJet
PROEXPO-COMMUNICATIONS10.12.2018 10:18 | Pressemeddelelse
China Shanghu Builds Itself into an International Health Demonstration Zone
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum